Results 311 to 320 of about 101,810 (380)
Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2‐Positive Cancers
Cancer Science, EarlyView.Overexpression of ABC transporters, especially ABCG2 and ABCB1, mediates acquired resistance to T‐DXd in HER2‐positive cancers. Inhibition of these transporters restored T‐DXd efficacy, highlighting efflux‐mediated resistance as a potential therapeutic target. ABSTRACT
Antibody–drug conjugates (ADCs) are emerging as a promising class of targeted cancer Yuya Murase, Shigeki Nanjo, Sachiko Arai, Sota Kondo, Hayato Koba, Yifeng Liu, Koji Fukuda, Shigeki Sato, Jun Kinoshita, Noriyuki Inaki, Tsukasa Ueda, Shunichi Nomura, Yuichi Tambo, Takahiro Shimizu, Masafumi Horie, Daichi Maeda, Richard W. Wong, Kazuyoshi Hosomichi, Takafumi Kobayashi, Satoshi Watanabe, Kenta Yamamura, Noriyuki Ohkura, Miki Abo, Seiji Yano +23 morewiley +1 more sourceEfficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial. [PDF]
BMC MedCheng Y, Tang H, Qing Y, Liu Y, Yang L, Dang W, Yu J, Li R, Liu H, Jiang Z, Sun H, Yin S, Cheng J, Li Z, Fan W, Zhang H, Du H, Fu Z, Ma X, Wu J, Duan L, Zhang R, Lin J, Da Z, Wei W, Zhai Q, Wu B, Yi X, Jin X, Ge J, Feng P, Liu Y. +31 moreeuropepmc +1 more sourceThe Impact of Next‐Generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Deep Penetrating Melanocytic Neoplasms
Journal of Cutaneous Pathology, EarlyView.ABSTRACT Background
Next‐generation sequencing (NGS) is becoming more commonly used for diagnosis in dermatopathology. It's critical to appraise its efficacy and limitations. Distinguishing benign deep penetrating nevi (DPN) from deep penetrating like‐melanoma (DPN‐M) is a challenging diagnostic scenario even for experienced dermatopathologists ...Julia Edwin Jeyakumar, Afua Konadu Addo, Haya Mary Beydoun, Shantel Olivares, Armita Bahrami, Thiagarajah Balamurugan, Raymond L. Barnhill, Willeke A. M. Blokx, Klaus J. Busam, Lorenzo Cerroni, Martin Cook, Arnaud de La Fouchardière, Lyn M. Duncan, David E. Elder, Peter Ferguson, Gerardo Ferrara, Iva Johansson, Jennifer S. Ko, Ji Eun Kwon, Gilles Landman, Cecilia Lezcano, Lori Lowe, Daniela Massi, Jane Messina, Daniela Mihic‐Probst, Douglas C. Parker, Margaret Redpath, Michael R. Sargen, Richard A. Scolyer, Christopher R. Shea, Michael Tetzlaff, Carlos Torres‐Cabala, Victor Tron, Xiaowei Xu, Iwei Yeh, Sook Jung Yun, Artur Zembowicz, Pedram Gerami +37 morewiley +1 more sourceIntroduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability. [PDF]
BioDrugsVeszelei I, Godman B, Aaltonen K, Selke GW, Garuolienė K, Cangini A, Kurdi A, Rodrigues AT, Pontes C, Torre C, Lunghi C, Burton E, Poplavska E, Jónsdóttir F, Petrova G, Langner I, Iaru I, Odnoletkova I, Slabý J, Gvozdanović K, Saastamoinen L, Laius O, Benkö R, Žiogaitė S, McTaggart S, Mueller T, de Pando T, Tesař T, Mitkova Z, Wettermark B. +29 moreeuropepmc +1 more sourceMaking Advanced Therapies Affordable and Accessible: Two Strategic Approaches
Developing World Bioethics, EarlyView.ABSTRACT
This article explores two complementary strategies for addressing the affordability and access challenges facing advanced therapies. As high development costs and limited market access have led to the withdrawal of several therapies, the article examines how these barriers create ‘valleys of death’ that prevent innovation from reaching ...Ubaka Ogbogu, Lauren Albrechtwiley +1 more sourceBexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC)
Epilepsia, EarlyView.Abstract Objective
This randomized, double‐blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).Dennis J. Dlugos, Ingrid E. Scheffer, Jacqueline A. French, David G. Vossler, Chad Orevillo, Shikha Polega, Randall Kaye, and the LP352‐201 Study Investigators, Kore Liow, Ena Zhu, Jennifer Waldron, Hayley Groubert, Alexis Anderson, Pavel Klein, Salman Hashmi, Shicong Ye, Anita Farhi, David Vossler, Dione M. Froman, Shannon L. Hoffman‐Huffaker, Ki Hyeong Lee, AnnaLyn Dallas, Amir Arain, Laura Beeler, Michael Macken, Irena Bellinski, Elizabeth Cunningham, James Renfroe, Shezsay Colbert, Robert Hogan, Patty Schaefer, Susan Shaw, Sheetal Desai, Ahmed Sadek, Haile Robertson, Kamil Detyniecki, Anabela Cieslicki, Ruben Kuzniecky, Sarah Goodman, Selim Benbadis, Marina Azevedo, Sami Aboumatar, Julie Biel, Nilika Singhal, Emerald Wan, Evan Fertig, Hannah Hart, Debopam Samanta, Sarah Hankins, Steven Wolf, Patricia Pena, Robert Nahouraii, M. J. Mari, David Burdette, Stephanie Mueller, Karen Keough, Victoria Henderson, Talitha Durgin, Terence O’Brien, Rafael Smith, Jack Germaine, Kate Riney, Lori Anthony, David Reutens, Kimberley Irwin, Michael Fahey, Melissa Batt, Stephanie Kaladis, Kasthoori Jeyachanthiran, Ingrid Scheffer, Rebecca Wharrie, Greesha Zacharia, Brittany Walsh, Heather Robinson, Sharon Ganter +74 morewiley +1 more sourceA randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures
Epilepsia, EarlyView.A randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures. Abstract Objectives
This randomized, double‐blind, placebo‐controlled study (NCT04557085), conducted in China, Japan, and the Republic of Korea, evaluated the efficacy and safety of ...Sang Kun Lee, Peimin Yu, Eunyeong Choe, Louis Ferrari, Kyoung Heo, Seung Bong Hong, Zhen Hong, Koji Iida, Yong Heui Jeon, Jiwon Jung, Marc Kamin, Kensuke Kawai, Ji Hyun Kim, Myung Won Kim, Xiaorong Liu, Jungshin Park, William E. Rosenfeld, Takamichi Yamamoto, Dong Zhou, Suiqiang Zhu, Sunita N. Misra +20 morewiley +1 more source